Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis

Authors:

Abstract
No abstract available
Funding Information
  • Biogen Inc

This publication has 17 references indexed in Scilit: